Payment overview · 2025
General Payments
$85.64
5 reported records · 3 companies
Healthcare provider profile · identity verified
Timothy Bushyhead
Allopathic & Osteopathic Physicians|Family Medicine · SKIATOOK, OK · NPI 1154718807
Verified facts
What the public records show
CMS Open Payments records show Timothy Bushyhead received $85.64 in general payments during 2025 across 5 reported records.
GlaxoSmithKline, LLC. accounted for 54.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.69 | 54.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.75 | 25.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.20 | 20.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $85.64 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $46.69 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 48 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 530 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 418 | 99 |
| Gabapentin | Gabapentin | 399 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 334 | 112 |
| Omeprazole | Omeprazole | 302 | 81 |
| Lisinopril | Lisinopril | 298 | 98 |
| Tamsulosin Hcl | Tamsulosin Hcl | 229 | 71 |
| Losartan Potassium | Losartan Potassium | 227 | 72 |
| Montelukast Sodium | Montelukast Sodium | 217 | 67 |
| Trazodone Hcl | Trazodone Hcl | 203 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 198 | 59 |
| Furosemide | Furosemide | 187 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 182 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 168 | 56 |
| Sertraline Hcl | Sertraline Hcl | 167 | 58 |
| Eliquis | Apixaban | 163 | 31 |
| Metformin Hcl Er | Metformin Hcl | 161 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 159 | 56 |
| Doxycycline Hyclate | Doxycycline Hyclate | 159 | 116 |
| Metformin Hcl | Metformin Hcl | 159 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 158 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 156 | 39 |
| Prednisone | Prednisone | 148 | 90 |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 42 |
| Meloxicam | Meloxicam | 129 | 41 |
| Alendronate Sodium | Alendronate Sodium | 112 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 108 | 44 |
| Carvedilol | Carvedilol | 101 | 31 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 97 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 29 |
| Potassium Chloride | Potassium Chloride | 93 | 35 |
| Amitriptyline Hcl | Amitriptyline Hcl | 92 | 26 |
| Azithromycin | Azithromycin | 89 | 61 |
| Buspirone Hcl | Buspirone Hcl | 85 | 26 |
| Simvastatin | Simvastatin | 78 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 19 |
| Tramadol Hcl | Tramadol Hcl | 77 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 71 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 68 | 21 |
| Ozempic | Semaglutide | 68 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 18 |
| Pregabalin | Pregabalin | 68 | 14 |
| Finasteride | Finasteride | 65 | 16 |
| Famotidine | Famotidine | 64 | 16 |
| Allopurinol | Allopurinol | 63 | 17 |
| Ondansetron Odt | Ondansetron | 60 | 25 |
| Fluconazole | Fluconazole | 59 | 37 |
| Ketoconazole | Ketoconazole | 58 | 25 |
| Xarelto | Rivaroxaban | 58 | 17 |
| Mounjaro | Tirzepatide | 57 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 23 |
| Azelastine Hcl | Azelastine Hcl | 54 | 32 |
| Clonazepam | Clonazepam | 53 | 11 |
| Cephalexin | Cephalexin | 51 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 48 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 47 | 13 |
| Mupirocin | Mupirocin | 47 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 14 |
| Glipizide | Glipizide | 46 | 15 |
| Jardiance | Empagliflozin | 44 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | suppressed |
| Celecoxib | Celecoxib | 43 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 12 |
| Memantine Hcl | Memantine Hcl | 43 | 14 |
| Levetiracetam | Levetiracetam | 41 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 17 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Alprazolam | Alprazolam | 37 | 11 |
| Methylprednisolone | Methylprednisolone | 37 | 31 |
| Propranolol Hcl | Propranolol Hcl | 37 | 11 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 37 | suppressed |
| Topiramate | Topiramate | 36 | 11 |
| Synthroid | Levothyroxine Sodium | 35 | 11 |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 34 | 24 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 29 |
| Atenolol | Atenolol | 30 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Novolog Flexpen | Insulin Aspart | 29 | 12 |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Colchicine | Colchicine | 25 | 13 |
| Lovastatin | Lovastatin | 25 | suppressed |
| Nystatin | Nystatin | 25 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 20 |
| Valsartan | Valsartan | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 14 | 11 |
| Primidone | Primidone | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 13 |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $85.64 · 5 records | GlaxoSmithKline, LLC. | AREXVY, Cologuard Collection Kit, TRELEGY ELLIPTA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error